Search
Doravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigational[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). … [L4562] Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic
Categories: Non-Nucleoside Reverse Transcriptase Inhibitors, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase InhibitorCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.
Zinc acetate
go.drugbank.com/drugs/DB14487ApprovedInvestigationalMixtures: Benadryl Bug Bite Relief, Children's Benadryl Bug Bite ReliefNafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. … A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug.
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalDue to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.
Nimodipine
go.drugbank.com/drugs/DB00393ApprovedInvestigationalIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.
Simvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigational[A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as simvastatin are thought to enter endothelial cells by passive diffusion, as … It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the
Products: Nu-simvastatin TabletsEscitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigationalto other SSRIs. … as compared to other agents in this class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: NEO ZENTIUS® 10 MG, NEO ZENTIUS® 20 MG COMPRIMIDOS